Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06803290 | Food Effect Study of VHX-896 in Healthy Volunteers | PHASE1 | COMPLETED | 24 | — | — | Jun 21, 2022 | Dec 27, 2022 | Jan 31, 2025 | 1 | United States |
| NCT04969211 | Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers | PHASE1 | COMPLETED | 25 | — | — | Jun 30, 2021 | Oct 13, 2021 | Jul 11, 2022 | 1 | United States |
As measured by plasma concentrations
as measured by plasma concentrations
As measured by the incidence of adverse events and clinically significant changes in laboratory values, ECG parameters, and vital signs
| Arm | Type | Description |
|---|---|---|
| Sequence A: fed then fasted | EXPERIMENTAL | - |
| Sequence B: fasted then fed | EXPERIMENTAL | - |
| Sequence A: VHX-896 then iloperidone | EXPERIMENTAL | - |
| Sequence B: Iloperidone then VHX-896 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VHX-896 | DRUG | Oral tablet |
| VHX-896 and iloperidone | DRUG | oral tablet |
| Iloperidone and VHX-896 | DRUG | oral tablet |
Inclusion Criteria: * Healthy male and/or female participants between 18 to 55 years (inclusive). * Have a Body Mass Index (BMI) of \> 18.0 and \< 30.0 kg/m2; (BMI = weight (kg)/ \[height (m)\]2). * Good health as determined by no clinically significant deviations from normal in medical history, cl...